Run Batch Effects Potentially Compromise the Usefulness of Genomic Signatures for Ovarian Cancer
作者： Keith A. Baggerly , Kevin R. Coombes , E. Shannon Neeley
关键词: Oncology 、 Compromise 、 Internal medicine 、 Medicine 、 Ovarian cancer 、 Cancer research
摘要:
sci-hub.se 参考文章(4)
David F. Ransohoff, Bias as a threat to the validity of cancer molecular-marker research Nature Reviews Cancer. ,vol. 5, pp. 142- 149 ,(2005) , 10.1038/NRC1550
Andrea H. Bild, Guang Yao, Jeffrey T. Chang, Quanli Wang, Anil Potti, Dawn Chasse, Mary-Beth Joshi, David Harpole, Johnathan M. Lancaster, Andrew Berchuck, John A. Olson, Jeffrey R. Marks, Holly K. Dressman, Mike West, Joseph R. Nevins, Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. ,vol. 439, pp. 353- 357 ,(2006) , 10.1038/NATURE04296
Holly K. Dressman, Andrew Berchuck, Gina Chan, Jun Zhai, Andrea Bild, Robyn Sayer, Janiel Cragun, Jennifer Clarke, Regina S. Whitaker, LiHua Li, Jonathan Gray, Jeffrey Marks, Geoffrey S. Ginsburg, Anil Potti, Mike West, Joseph R. Nevins, Johnathan M. Lancaster, An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer Journal of Clinical Oncology. ,vol. 25, pp. 517- 525 ,(2007) , 10.1200/JCO.2006.06.3743
Andrew Berchuck, Edwin S Iversen, Johnathan M Lancaster, Jennifer Pittman, Jingqin Luo, Paula Lee, Susan Murphy, Holly K Dressman, Phillip G Febbo, Mike West, Joseph R Nevins, Jeffrey R Marks, None, Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers Clinical Cancer Research. ,vol. 11, pp. 3686- 3696 ,(2005) , 10.1158/1078-0432.CCR-04-2398